成人使用GLP-1受体激动剂术后吸入性肺炎
该回顾性队列研究利用MarketScan商业索赔数据库,纳入2020年4月1日至2022年9月30日期间接受14种常见手术之一、年龄≥18岁且术前90天无肺炎或急性呼吸衰竭史的患者366 476例。其中5931例(1.6%)术前有GLP-1受体激动剂处方。多因素logistic回归调整患者和手术特征后,GLP-1受体激动剂使用者与非使用者术后30天吸入性肺炎的比值无显著差异(OR 0.78,95%CI 0.57-1.06,P=.12)。作者认为,这一结果提示可能有必要重新评估GLP-1受体激动剂的术前停药指南。
要点
- 366 476例手术患者中5931例(1.6%)术前有GLP-1受体激动剂处方,术后30天吸入性肺炎比值与非使用者无显著差异(OR 0.78,95%CI 0.57-1.06,P=.12)。
- GLP-1受体激动剂使用者中女性3502例(59.0%)vs 非使用者203 288例(56.4%),合并肥胖和糖尿病者2819例(47.5%)vs 24 635例(6.8%)。
- 研究排除术前90天内有肺炎或急性呼吸衰竭史、年龄<18岁及接受多次手术者。
- 作者认为该发现提示可能有必要重新评估GLP-1受体激动剂的术前停药指南。
适用人群与场景
- 接受14种常见手术之一、年龄≥18岁的患者,数据来自MarketScan商业索赔数据库,手术日期为2020年4月1日至2022年9月30日。
- 排除:年龄<18岁、接受多次手术、术前90天内有肺炎或急性呼吸衰竭史的患者。
研究设计与关键结果
- 回顾性队列研究,纳入366 476例患者(中位年龄53岁,IQR 43-62岁),其中女性56.4%。
- 5931例(1.6%)术前有GLP-1受体激动剂处方;使用者中女性3502例(59.0%)vs 非使用者203 288例(56.4%),合并肥胖和糖尿病者2819例(47.5%)vs 24 635例(6.8%)。
- 主要终点术后30天吸入性肺炎:调整后GLP-1受体激动剂使用者与非使用者比值无显著差异(OR 0.78,95%CI 0.57-1.06,P=.12)。
证据类型、等级与局限
- 证据类型:回顾性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,术前使用GLP-1受体激动剂与术后短期吸入性肺炎无显著关联,这一发现提示可能有必要重新评估GLP-1受体激动剂的术前停药指南。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been increasingly prescribed for weight management in recent years. However, little is known about whether preoperative GLP-1 RA use is associated with a greater risk of complications after surgery.
OBJECTIVE: To investigate whether preoperative GLP-1 RA use is associated with postoperative aspiration pneumonia among patients undergoing common surgical procedures.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study, conducted using MarketScan commercial claims databases, included patients who underwent 1 of 14 common surgical procedures from April 1, 2020, to September 30, 2022. Individuals who were younger than 18 years, underwent multiple surgical procedures, or had a preoperative history of pneumonia or acute respiratory failure in the 90 days preceding surgery were excluded. Data were analyzed from December 2023 to March 2024.
MAIN OUTCOME AND MEASURES: The primary outcome was aspiration pneumonia in the 30-day postoperative period. Multivariable logistic regressions were performed, adjusting for patient and surgical characteristics.
RESULTS: This study included 366 476 patients (median age, 53 years [IQR, 43-62 years]), of whom 56.4% were women. In the cohort, 5931 patients (1.6%) had a preoperative prescription for a GLP-1 RA. Patients using GLP-1 RAs were more likely to be female (3502 [59.0%] vs 203 288 [56.4%]) and diagnosed with both obesity and diabetes (2819 [47.5%] vs 24 635 [6.8%]) compared with nonusers. Adjusted analysis showed no significant differences in the odds of postoperative pneumonia (odds ratio, 0.78; 95% CI, 0.57-1.06; P = .12) between GLP-1 RA users and nonusers.
CONCLUSIONS AND RELEVANCE: This cohort study found no significant association between the preoperative use of GLP-1 RAs and short-term postoperative aspiration pneumonia despite growing concerns about the adverse effects of these medications after surgery. This finding suggests that it may be beneficial to reassess the preoperative withholding guidelines for GLP-1 RAs.
参考来源
- Chen YH, Zink T, Chen YW, et al. Postoperative Aspiration Pneumonia Among Adults Using GLP-1 Receptor Agonists. JAMA Netw Open. 2025. PMID: 40036031. doi:10.1001/jamanetworkopen.2025.0081
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。